Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Global Operations | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Sale · Disposed 9,989 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 9,989 | $32.19 | $321,546.91 |
DisclosureSEC source: 0001193125-26-277490 · ownership.xml · nonDerivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-257344 · ownership.xml · derivative · entry 3 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,392 Underlying: Ordinary Shares · 16,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on June 3, 2024, with 16,195 vested on each of June 3, 2025 and June 3, 2026, 16,195 vesting on June 3, 2027, and 16,197 vesting on June 3, 2028. F5 · derivative.expiration_date: Restricted share units were granted on June 3, 2024, with 16,195 vested on each of June 3, 2025 and June 3, 2026, 16,195 vesting on June 3, 2027, and 16,197 vesting on June 3, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 16,195 | $32.87 | $532,329.65 |
DisclosureSEC source: 0001193125-26-257344 · ownership.xml · nonDerivative · entry 2 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,989 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-257344 · ownership.xml · nonDerivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098473 · ownership.xml · derivative · entry 3 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,887 Underlying: Ordinary Shares · 17,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 17,295 | $31.67 | $547,704.98 |
DisclosureSEC source: 0001193125-26-098473 · ownership.xml · nonDerivative · entry 2 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,989 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098473 · ownership.xml · nonDerivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:14 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 33,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096552 · ownership.xml · derivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,424 Underlying: Ordinary Shares · 33,424 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 16,195 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-082498 · ownership.xml · derivative · entry 3 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,587 Underlying: Ordinary Shares · 16,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 3, 2024 with 16,195 vested on June 3, 2025, 16,195 vesting on each of June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028. F4 · derivative.expiration_date: Restricted share units were granted on June 3, 2024 with 16,195 vested on June 3, 2025, 16,195 vesting on each of June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 6,206 | $17.02 | $105,627.98 |
DisclosureSEC source: 0000950170-25-082498 · ownership.xml · nonDerivative · entry 2 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,989 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 16,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-082498 · ownership.xml · nonDerivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:10 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 69,182 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035508 · ownership.xml · derivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,182 Underlying: Ordinary Shares · 69,182 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F2 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 11:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 64,782 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069074 · ownership.xml · derivative · entry 1 Shields Matthew · CIK 0002025621 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,782 Underlying: Ordinary Shares · 64,782 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 3, 2024, with 16,195 vesting on each of June 3, 2025, June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028. F2 · derivative.expiration_date: Restricted share units were granted on June 3, 2024, with 16,195 vesting on each of June 3, 2025, June 3, 2026 and June 3, 2027, and 16,197 vesting on June 3, 2028. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.